Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_2
1
20%
Ph early_phase_1
1
20%
Ph phase_1
2
40%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 12 (50.0%)
Phase 21 (25.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

NCT01223898
completedearly_phase_1

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

NCT01275586
completed

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

NCT01289054
completedphase_1

Pharmacokinetic Comparison of XS003 and Tasigna

NCT02068898
completedphase_2

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

NCT01261429

Clinical Trials (5)

Showing 5 of 5 trials
NCT01223898Phase 1

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Completed
NCT01275586Early Phase 1

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Completed
NCT01289054

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

Completed
NCT02068898Phase 1

Pharmacokinetic Comparison of XS003 and Tasigna

Completed
NCT01261429Phase 2

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5